Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
September 16, 2019 Cover
Volume 97, Issue 36
On Sept. 17, 1999, Jesse Gelsinger died after receiving an experimental gene therapy from James Wilson’s lab at the University of Pennsylvania. That tragedy waylaid Wilson’s career and almost shut down the whole field. Wilson and his team put their heads down and spent the next decade searching for safer gene therapies. Today, his lab’s $70 million annual budget and bevy of biotech partnerships are fueling the gene therapy explosion.
The resurgence was never a sure thing.
Here’s how it happened.
Cover image:The polarizing pioneer guides a gene therapy renaissance
Credit: Matthew Bender
Volume 97 |
Issue 36
Alexa and your phone are getting schooled in chemistry
Software developers are prepping standard voice-activated assistants to work in chemical and pharmaceutical research
The toilet gets a makeover
The Gates Foundation challenges researchers to design self-contained waste processing systems for low-resource communities
-
Charge detection mass spectrometry measures molecular structures too big for regular mass spec
Scientists are paying more attention to the technique as a commercial instrument proves up to the task
-
Scientific instrument makers weigh the lure of outside money
When it comes to raising funds for growth, small instrument companies look to private equity firms, but sometimes reluctantly
-
UN summit on climate draws world’s gaze
Student-led protests call for government action to prevent catastrophic changes
-
The ins and outs of hiring pipelines
Whether they’re fair or not, these established networks give some job seekers an advantage
ADVERTISEMENT
Science Concentrates
Chemists build the tiniest spectrometer from a single nanowire
Device could pave the way for miniature analytical instruments
Business & Policy Concentrates
- BASF and Linde plan to bolster helium supplies
- Gene editing startup Trucode raised $34 million to test an alternative to CRISPR
- Chemical companies spar over PFAS pollution liability in US
- CSB nominee Katherine Lemos sails through confirmation hearing
- Mallinckrodt will sell BioVectra to the investment firm H.I.G.
